199 related articles for article (PubMed ID: 2505028)
1. Pergolide and selegiline for Parkinson's disease.
Med Lett Drugs Ther; 1989 Sep; 31(800):81-3. PubMed ID: 2505028
[No Abstract] [Full Text] [Related]
2. Selegiline for Parkinson's disease.
Calesnick B
Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
[TBL] [Abstract][Full Text] [Related]
3. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
Amato L; Nava L; Rizzo M; Piccoli F
Riv Neurol; 1985; 55(1):46-52. PubMed ID: 3927468
[No Abstract] [Full Text] [Related]
4. [Therapeutic strategies in Parkinson's disease].
Shoulson I
Arch Neurobiol (Madr); 1991; 54(6):277-81. PubMed ID: 1687429
[No Abstract] [Full Text] [Related]
5. Deprenyl in Parkinson's disease.
Lancet; 1982 Sep; 2(8300):695-6. PubMed ID: 6126632
[No Abstract] [Full Text] [Related]
6. Adjuvant drugs in the treatment of on-off phenomena in Parkinson's disease.
Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Bihari K
Adv Neurol; 1984; 40():549-56. PubMed ID: 6421113
[No Abstract] [Full Text] [Related]
7. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
[No Abstract] [Full Text] [Related]
8. Pergolide and Parkinson's disease: new preparation. No clear benefit.
Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
[TBL] [Abstract][Full Text] [Related]
9. Deprenyl and the progression of Parkinson's disease.
Science; 1990 Jul; 249(4966):303-4. PubMed ID: 2115691
[No Abstract] [Full Text] [Related]
10. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
11. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
Rinne UK
J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Parkinson's disease.
Eadie MJ
Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
[TBL] [Abstract][Full Text] [Related]
13. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
Tetrud JW; Langston JW
J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
[TBL] [Abstract][Full Text] [Related]
14. L-deprenyl in the treatment of Parkinson's disease.
Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G
J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of the effectiveness of combined (L-dopa + Jumex) therapy based on a multicentric double blind study].
Tariska I; Gallai M
Orv Hetil; 1983 Sep; 124(38):2309-14. PubMed ID: 6415577
[No Abstract] [Full Text] [Related]
16. (-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages.
Giovannini P; Martignoni E; Piccolo I; Pacchetti C; Grassi MP; Nappi G; Caraceni T
J Neural Transm Suppl; 1986; 22():235-46. PubMed ID: 3097258
[TBL] [Abstract][Full Text] [Related]
17. Selegiline in the early and late phases of Parkinson's disease.
Csanda E; Tárczy M
J Neural Transm Suppl; 1987; 25():105-13. PubMed ID: 3123597
[TBL] [Abstract][Full Text] [Related]
18. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
Birkmayer W; Birkmayer GD
J Neural Transm Suppl; 1986; 22():219-25. PubMed ID: 3097256
[TBL] [Abstract][Full Text] [Related]
19. Pergolide mesylate: four years experience in Parkinson's disease.
Tanner CM; Goetz CG; Glantz RH; Klawans HL
Adv Neurol; 1987; 45():547-9. PubMed ID: 3825732
[No Abstract] [Full Text] [Related]
20. Parallel double-blind study of pergolide in Parkinson's disease.
Jankovic J; Orman J
Adv Neurol; 1987; 45():551-4. PubMed ID: 3548265
[No Abstract] [Full Text] [Related]
[Next] [New Search]
